



Significant and sustained reductions in diabetes-related hospitalizations after starting FreeStyle Libre systems*¹

RELIEF STUDY*¹

Real-world evidence on use of the FreeStyle Libre systems and hospitalizations from acute diabetes events (ADEs)



Study included over **70,000** patients



Significant and sustained reduction in hospitalizations for ADEs




Patients were assessed **24 months** after FreeStyle Libre systems initiation



Continuous and consistent use of FreeStyle Libre systems

Reduced rates of hospitalization for ADEs were sustained over 24 months^{†1}




After 24 months vs. 12 months prior to initiation of FreeStyle Libre systems

Reduction of hospitalizations for ADEs was driven by **fewer diabetic ketoacidosis admissions** (-53% in T1D and -47% in T2D)

Continuous and consistent use of FreeStyle Libre systems

88% of patients continued after 24 months*¹




ADEs= acute diabetes events; T1D= type 1 diabetes; T2D= type 2 diabetes; DKA= diabetic ketoacidosis.

*Data from this study was collected with the outside US version of FreeStyle Libre 14 day system. FreeStyle Libre 2 and FreeStyle Libre 3 have the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore the study data is applicable to all products. †ADEs included severe hypoglycemia, DKA, diabetes-related coma and hyperglycemia. See Important Safety Information on next page. **Reference: 1.** Riveline, J-P. *Diabetes Technol Ther* (2022): <https://doi.org/10.1089/dia.2022.0085>.




In patients with T2D on basal insulin therapy*†

Reduced rates of hospitalizations for ADEs were sustained over 24 months†



Recommend FreeStyle Libre systems to all your T1D and T2D patients



FreeStyle Libre 2 and FreeStyle Libre 3 systems are indicated for use in people with diabetes age 4 and older.

The FreeStyle Libre 2 or 3 apps are only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the apps. Use of the apps may require registration with LibreView.

Medicare coverage is available for the FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third party payor criteria apply.

Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.

ADEs = acute diabetes events; T1D= type 1 diabetes; T2D= type 2 diabetes.

*Selection period for this sub-group analysis between 01/08/2017 to 12/31/2018. 5,933 patients were identified during the selection period. 5,933 patients were on basal insulin, including 1,994 who started in 2017 and 3,939 who started in 2018. †Data from this study was collected with the outside US version of FreeStyle Libre 14 day system.

FreeStyle Libre 2 and FreeStyle Libre 3 have the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore the study data is applicable to all products.

Reference: 1. Guerci, B. *Diabetes Technol Ther* (2022): <https://doi.org/10.1089/dia.2022.0271>.

Important Safety Information

FreeStyle Libre 14 day system: Failure to use FreeStyle Libre 14 day system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or <https://www.FreeStyle.abbott/us-en/safety-information.html> for safety info.

FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre 2 or FreeStyle Libre 3 systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or <https://www.FreeStyle.abbott/us-en/safety-information.html> for safety info.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.

© 2023 Abbott. ADC-72079 v2.0 9/23